Probiotic enumeration in foods and beverages remains anchored in culture dependent colony-forming unit (CFU) counts, the regulatory gold standard for label compliance. However, culturability does not fully equate to viability as environmental stresses can convert probiotic cells into a viable but non-culturable (VBNC) state, where they remain metabolically active but undetectable by CFU counts. Microencapsulation can provide a degree of protection to probiotics against stress; nevertheless, this blind spot in quantification forces manufacturers to overdose formulations or risk non-compliance with health benefits claims. Thus, the efficacy of probiotics may be underestimated when evaluation relies solely on CFU, creating a false dichotomy between VBNC and non-viable cells. Culture-independent methods, including flow cytometry quantification of active fluorescent units (AFUs), viability PCR/dPCR, and rRNA-targeted Flow-FISH, can aid closing this gap by detecting metabolically active cells non-detectable by culturing, providing complementary quantification data to CFU counts alone. Understanding the relationship between quantification by culture and culture-independent methods provides a more accurate measure of probiotic dose delivery in functional foods and beverages. This review covers the current understanding of VBNC state, including induction, detection, and resuscitation in probiotics, with emphasis on experimental controls that differentiate true VBNC resuscitation from population growth. Case studies in Lactobacillus and Bifidobacterium illustrate triggers, molecular mechanisms, and methodological advances. Finally, guidance is provided for the development of an integrated quantification approach that reconciles culture-dependent and culture-independent data, ultimately aiming to improve CFU count accuracy through the controlled resuscitation of VBNC cells.
Probiotic efficacy may depend on reliable intestinal exposure, yet clinical evidence linking delivery engineering to measurable microbiome responses in humans remains limited. We compared two active doses of microencapsulated Lacticaseibacillus rhamnosus GG in 26 healthy adults in a randomised, double-blind, two-period crossover trial. Participants received 2 × 109 CFU/day (2BN) and 6 × 109 CFU/day (6BN) for 28 days each in a yoghurt drink, separated by a 14-day washout. Gastrointestinal metrics, tolerance, bowel-habit metrics, and the measured biomarkers remained stable across both doses. By metagenomics, L. rhamnosus was detected in stools in 8/23 participants at baseline, 12/23 participants after 6BN, and 10/23 after 2BN. These data represent marginal prevalence counts and does not establish individual acquisition, viability, persistence or colonisation. Species-level PERMANOVA on Aitchison distances showed a significant within-period microbiome shift during 6BN that was not observed during 2BN. There were directional changes in commensal anaerobic taxa and metagenomic functional modules related to vitamin/cofactor biosynthesis, polyamine biosynthesis, glycogen degradation, multidrug-resistance efflux pumps, and tetrahydrobiopterin biosynthesis. Microencapsulated L. rhamnosus GG was safe and well tolerated at both doses.